RBC Capital analyst Rishi Jaluria raised the firm’s price target on Hinge Health (HNGE) to $65 from $55 and keeps an Outperform rating on the shares. The company delivered another solid quarter of revenue outperformance and margin expansion with all metrics coming in above consensus, the analyst tells investors in a research note. RBC adds it continues to see a long runway ahead as Hinge scales into a growing total addressable market.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HNGE:
- Hinge Health Earnings Call Signals Profitable Growth
- Hinge Health Lifts 2026 Outlook After Record Quarter
- Hinge Health Buy Rating Reiterated on Growth Momentum and Migraine Expansion, Price Target Maintained at $72
- Analyst Reiterates Buy on Hinge Health, Citing Near‑Term Outperformance Potential and Long‑Term Growth from New Migraine Care Program
- Hinge Health launching migraine treatment program, WSJ reports